BW 755C

Drug Profile

BW 755C

Latest Information Update: 14 Mar 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-ischaemics; Antiarrhythmics; Antiepileptic drugs; Antirheumatics; Neuroprotectants; Pyrazoles; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary artery restenosis; Thrombosis
  • Discontinued Arrhythmias; Rheumatic disorders

Most Recent Events

  • 14 Mar 2000 No-Development-Reported for Coronary artery restenosis in Canada (Unknown route)
  • 14 Mar 2000 No-Development-Reported for Thrombosis in Canada (Unknown route)
  • 24 Mar 1997 A preclinical study has been added to the Ischaemic Heart Diseasa and Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top